

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/647,739	08/25/2003		Manuel Guzman Pastor	A34700 PCT USA-I	2301
21003	7590	11/21/2006		EXAMINER	
BAKER &		N. A 77 A	ANDERSON, JAMES D		
30 ROCKEFELLER PLAZA 44TH FLOOR				ART UNIT	PAPER NUMBER
NEW YORI	NEW YORK, NY 10112-4498			1614	
•				DATE MAILED: 11/21/2006	5

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
	10/647,739	GUZMAN PASTOR ET AL.					
Office Action Summary	Examiner	Art Unit					
	James D. Anderson	1614					
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address					
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period versions of the period of th	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be timused apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE.	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).					
Status							
1)⊠ Responsive to communication(s) filed on <u>03 A</u>	oril 2006.						
	action is non-final.						
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims							
4)⊠ Claim(s) <u>16</u> is/are pending in the application.							
	4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.							
6)⊠ Claim(s) <u>16</u> is/are rejected.							
7) Claim(s) is/are objected to.							
8) Claim(s) are subject to restriction and/or	r election requirement.						
Application Papers							
9) The specification is objected to by the Examine	r						
10) The drawing(s) filed on is/are: a) acce		Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correct							
11) The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.					
Priority under 35 U.S.C. § 119							
12)⊠ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a)⊠ All b)□ Some * c)□ None of:							
1. Certified copies of the priority documents have been received.							
2. Certified copies of the priority documents have been received in Application No. PCT/ES00/00450.							
3. Copies of the certified copies of the priority documents have been received in this National Stage							
application from the International Bureau	ı (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list	of the certified copies not receive	d.					
Attachment(s)							
1) Motice of References Cited (PTO-892) 2) D Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) Ll Interview Summary Paper No(s)/Mail Da						
3) Information Disclosure Statement(s) (PTO/SB/08)	5) Notice of Informal P						
Paper No(s)/Mail Date	6)						

Application/Control Number: 10/647,739

Art Unit: 1614

DETAILED ACTION

Applicants' arguments, filed 4/3/2006, have been fully considered but they are not deemed to be persuasive. Rejections and/or objections not reiterated from previous Office Actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application.

Status of the Claims

Claim 16 is currently pending and is the subject of this Office Action.

Priority

Acknowledgment is made of applicant's claim for foreign priority under 35 U.S.C. § 119(a)-(d). The certified copy has been filed in parent Application No. PCT/ES00/00450, filed on November 22, 2000. A certified English translation was also filed in the parent application.

Claim Rejections - 35 USC § 112 - Second Paragraph

The following is a quotation of the second paragraph of 35 U.S.C. § 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 16 is rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Application/Control Number: 10/647,739

Art Unit: 1614

In the instant case, recitation of the phrase "including man" is indefinite because it is not clear whether this phrase is a claim limitation (i.e. is the intention to limit the treatment to only man).

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. § 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claim 16 is rejected under 35 U.S.C. § 102(b) as being anticipated by The Merck Manual of Diagnosis and Therapy.

The instant claim is drawn to the treatment of one or more glioblastomas in a mammal comprising administering Δ^9 -tetrahydrocannibinol or Δ^8 -tetrahydrocannibinol.

The reference teaches that nausea and vomiting may be due to symptoms of disease processes or responses to stimuli such as drugs (antineoplastic chemotherapeutics), radiation, or motion (page 1281). Dronabinol (Δ-9-tetrahydrocannibinol; THC) is approved to treat nausea and vomiting caused by cancer chemotherapy in patients who have failed to respond to conventional antiemetic therapy (page 1284). Doses are typically 5-15 mg/m² by oral administration (Table 103-7, page 1282).

The Merck Manual inherently teaches the claimed method because it teaches the administration of THC to patients to treat nausea and vomiting induced by chemotherapy or radiation treatment. As such, when THC is administered as an antiemetic to a patient undergoing

Application/Control Number: 10/647,739

Art Unit: 1614

chemotherapy or radiation treatment for a glioblastoma, it will inherently treat the glioblastoma as instantly claimed. Further, headache and vomiting are often symptoms of intracranial neoplasms such as glioblastomas (page 1478-1479). Thus, when a patient presenting symptoms of nausea, headache, and/or vomiting is administered THC as an antiemetic, such administration will also inherently treat the underlying glioblastoma (if one exists).

It is the examiner's position that the prior art inherently teaches the claimed method because applicants have failed to sufficiently distinguish the patient population being treated in claim 16 from the larger population of patients who may present with nausea and vomiting due to chemotherapy and radiation treatment. Some of these patients are being treated for a glioblastoma. Thus, the prior art inherently teaches a method of treating a glioblastoma by administering THC.

Conclusion

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to James D. Anderson whose telephone number is 571-272-9038. The examiner can normally be reached on MON-FRI 9:00 am - 5:00 pm EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel can be reached on 571-272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

Art Unit: 1614

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

James D. Anderson, Ph.D.

Patent Examiner

AU 1614

November 14, 2006

PHYLLIS SPIVACK
PRIMARY EXAMINER

Phyllus Spivack

Page 5